Tedis Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Tedis Pharmaceutical Import Records from India — 2 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Tedis — Pharmaceutical Importer Profile (2026) | 2 Products, $1.8M Trade | TransData Nexus

Tedis

Pharmaceutical Importer · France · Advanced Antibiotics Focus · $1.8M Total Trade · DGFT Verified

Tedis is a pharmaceutical importer based in France with a total trade value of $1.8M across 2 products in 1 therapeutic categories. Based on 48 verified import shipments from Indian Customs (DGFT) records, Tedis is the #1 buyer in 1 product including Benzylpenicillin. Tedis sources from 60 verified Indian suppliers, with Alde Medi Impex Limited accounting for 13.2% of imports.

Tedis — Import Portfolio & Supplier Network

Tedis import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Tedis?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Alde Medi Impex Limited	$2.3M	185	13.2%
Vinccent Biotech Private Limited	$1.2M	235	7.2%
Medreich Limited	$1.1M	41	6.4%

What Formulations Does Tedis Import?

Formulation	Value	Ships
Benzathine benzylpenicilline 2.4miu INJ	$309.3K	7
Pharma.drugs&medicines-misoclear	$234.2K	6
Herbal cough syrup ( brand kuka )-batchno 1787-p mfg dt 01/2024 exp dt	$146.0K	3
Misoclear tabs (misoprostol 200 MCG	$129.2K	4
Klavmox lb1125mg TAB.amoxicillin & clavulanate potassium TAB.with lactic acid	$122.5K	5
Pharmaceuticals products (medicine	$109.0K	9
Pharmaceutical products-alfer	$100.0K	2
Alozol 400MG tablet batch no ph01202	$100.0K	2
Zylocef 1GM injection (export) ceftriaxone sodium USP sterile for injection 1000MG +sterile water for INJ	$100.0K	2
Pharmaceuticals drugs medicine misoclear tabs misoprostol 200 MCG tabs mfg dtjan 2023 exp dt dec	$99.6K	2
Pharmaceuticals products - micfox 200 tablet (export) b.no: mcx2-12 ,mfg dt: jan-25 ,exp dt	$97.2K	2
Herbal cough syrup ( brand kuka )-batchno 0035-q mfg dt 04/2024 exp dt	$80.5K	3
Niflox tablets(ofloxacin 200MG and ornidazole 500MG tablets)	$74.4K	3
Pharmaceuticals products - demoxin cv 1125 sachet export amoxiciilin BP as trihydrate equivalent to amoxiciilin 1000 MG	$67.0K	2
Amoxicillin and potassium clavulanate	$66.6K	6

Tedis imports 1,580 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Benzylpenicillin	Advanced Antibiotics	$1.6M	34	40.9%	1
2	Ornidazole	Advanced Antibiotics	$225.7K	14	1.3%	8

Tedis imports 2 pharmaceutical products across 1 categories into France totaling $1.8M. The company is the #1 buyer for 1 product: Benzylpenicillin.

Tedis — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Tedis is a French pharmaceutical company established in 1989, specializing in the distribution and export of pharmaceutical and healthcare products. Headquartered in Villebon-sur-Yvette, Île-de-France, Tedis has expanded its operations to over 20 countries across Europe, Africa, and Asia. The company partners with more than 50 laboratories, facilitating the supply, promotion, and distribution of their products while adhering to ethical standards and local regulations. (tedis.fr)

Tedis offers a comprehensive range of services, including exclusive distribution, wholesale distribution, cold chain logistics, and pharmaceutical affairs. Their expertise encompasses regulatory affairs, traceability, pharmacovigilance, and compliance with good distribution practices. This diverse service portfolio positions Tedis as a key player in the pharmaceutical supply chain, ensuring efficient and secure delivery of healthcare products to various markets. (tedis.fr)

2Distribution Network

Tedis operates an extensive distribution network with subsidiaries and facilities across three continents, including Europe, Africa, and Asia. In France, the company has established a 1,500 m² temperature-controlled warehouse in Wissous, dedicated to logistics and storage. This facility ensures the secure handling of temperature-sensitive medications, reagents, and vaccines. (tedis.fr)

Internationally, Tedis has expanded its presence with subsidiaries in countries such as Burkina Faso, Ivory Coast, Togo, and Vietnam. These subsidiaries operate multiple agencies, providing daily supply to pharmacies, public health institutions, and local healthcare stakeholders in both urban and rural areas. The company's efficient logistics platforms and dedicated cold chain management facilities enable end-to-end integration of the supply chain, enhancing access to medications globally. (tedis.fr)

3Industry Role

Tedis functions as a primary wholesaler and exclusive distributor in the pharmaceutical supply chain. By partnering with over 50 laboratories, the company facilitates the supply, promotion, and distribution of pharmaceutical and healthcare products across various markets. Their comprehensive service offerings, including cold chain logistics and regulatory affairs, underscore their pivotal role in ensuring the efficient and secure delivery of healthcare products. (tedis.fr)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Tedis

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Tedis's sourcing strategy exhibits a high degree of concentration, with a significant portion of their imports originating from a select group of Indian suppliers. The top five suppliers account for approximately 42.6% of the total import value, indicating a reliance on these key partners. This concentrated sourcing approach may present risks related to supply chain disruptions, such as production delays or regulatory changes affecting these suppliers.

However, the extensive number of unique suppliers—60 in total—suggests a diversified sourcing strategy that mitigates the impact of potential disruptions from any single supplier. The high number of shipments (48) and unique formulations (1,580) imported from India further indicate a stable and well-established relationship between Tedis and its Indian suppliers. This diversification and the volume of transactions may help in maintaining a resilient supply chain.

2Supply Chain Resilience

Tedis's supply chain resilience is bolstered by its diversified sourcing strategy, encompassing a wide range of suppliers and formulations. The company's partnerships with 60 unique Indian suppliers and the importation of 1,580 unique formulations demonstrate a broad and adaptable supply chain. This diversity allows Tedis to mitigate risks associated with dependency on a single supplier or product line.

Additionally, Tedis's investment in cold chain logistics, as evidenced by their 1,500 m² temperature-controlled warehouse in Wissous, enhances the company's ability to manage and distribute temperature-sensitive products effectively. This infrastructure supports the resilience of their supply chain by ensuring the secure handling and delivery of sensitive pharmaceutical products. (tedis.fr)

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the Agence nationale de sécurité du médicament et des produits de santé (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of medicinal products available in the French market. The French Public Health Code outlines the legal framework governing the manufacture, import, and distribution of pharmaceutical products. Key provisions include requirements for import authorizations, compliance with good distribution practices, and adherence to safety features for medicinal products.

For Indian pharmaceutical companies seeking to export to France, obtaining a marketing authorization from ANSM is mandatory. This process involves submitting detailed documentation, including product information, manufacturing processes, and quality control measures, to demonstrate compliance with French and European Union regulations. The authorization ensures that imported products meet the necessary standards for safety and efficacy before entering the French market.

2Import Licensing & GMP

Import licensing in France requires that each import operation of finished pharmaceutical products be authorized by ANSM. This authorization process involves providing detailed information about the product, including its name, composition, pharmaceutical form, dosage, and method of administration. Additionally, the quantities imported and the country of origin must be specified. For medicinal products other than finished products, import authorizations may cover a series of import operations over a specified period.

Tedis — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Tedis's focus on advanced antibiotics, particularly Benzylpenicillin, indicates a strategic alignment with the high demand for effective antimicrobial therapies in the French market. The substantial import value of Benzylpenicillin ($1.6 million) and its ranking as the top product highlight its critical role in Tedis's product portfolio. The inclusion of Ornidazole, an antiprotozoal agent, suggests a diversification strategy to address a broader spectrum of infectious diseases. This product mix reflects Tedis's commitment to providing comprehensive healthcare solutions that meet the evolving needs of the French healthcare system.

The market demand for these products is driven by the prevalence of infectious diseases and the need for effective treatments. Tedis's strategic importation of these products ensures a consistent supply, supporting healthcare professionals in delivering timely and effective care to patients. By focusing on these therapeutic areas, Tedis positions itself as a key contributor to public health in France.

2Sourcing Profile

Tedis's sourcing strategy emphasizes the importation of finished pharmaceutical formulations from India, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows Tedis to leverage India's robust pharmaceutical manufacturing capabilities, ensuring access to high-quality, ready-to-market products. The importation of 1,580 unique formulations from 60 suppliers indicates a diversified and comprehensive procurement strategy. This diversity enables Tedis to meet the varied needs of the French market and mitigate risks associated with dependency on a single supplier or product line.

Frequently Asked Questions — Tedis

What products does Tedis import from India?

Tedis imports 2 pharmaceutical products across 1 categories. Top imports: Benzylpenicillin ($1.6M), Ornidazole ($225.7K).

Who supplies pharmaceuticals to Tedis from India?

Tedis sources from 60 verified Indian suppliers. The primary supplier is Alde Medi Impex Limited (13.2% of imports, $2.3M).

What is Tedis's total pharmaceutical import value?

Tedis's total pharmaceutical import value from India is $1.8M, based on 48 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Tedis focus on?

Tedis imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Tedis Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.